

GE HEALTHCARE & CELL THERAPY

A TIMELINE BY EVOLUTION GLOBAL

GE acquires Disposable Bioreactor company Wave Biotech. **APR 2007**

GE acquires PAA Laboratories, a developer & supplier of cell culture media. **AUG 2011**

GE sublicense Stem Cell Theranostics intellectual property relating to the use of human induced pluripotent stem cells, enabling SCT to develop & manufacture cardiomyocytes derived from stem cells for use in drug discovery and toxicity. **JULY 2015**

Kite Pharma & GE announce strategic collaboration to automate manufacturing of engineered T-Cell therapies. **DEC 2015**

GE Ventures & Mayo Clinic launch Vitruvian Networks, which will provide therapy producers with a state-of-the-art software and manufacturing platform to bring the "Internet of things" to cell & gene therapies. **APR 2016**

GE acquires British cryogenic processing company Asymptote for an undisclosed amount. **APR 2017**

JUNE 2009 GE announces alliance with Geron Corporation to develop first generation human embryonic stem cell-based therapies.

JAN 2014 GE acquire Thermo Fisher's HyClone™ cell culture media and sera, and gene modulation and magnetic bead businesses.

AUG 2015 The Cooperative Research Centre for Cell Therapy Manufacturing, GE Healthcare and Health Industries South Australia sign an agreement that will lay the foundation for a long-term partnership focussed on advancing Australia's cell therapy industry.

JAN 2016 Toronto-based Centre for Commercialization of Regenerative Medicine announced, with GE and the Canadian government each investing \$20 million CAD.

JUNE 2016 GE acquires the Biosafe Group, a supplier of integrated cell bioprocessing systems, for an undisclosed amount.

APR 2017 GE announce partnership with Cellular Biomedicine Group to develop CAR-T & stem cell production technologies to support its aim of creating 10,000 cancer therapies & 10,000 osteoarthritis treatments a year.